Carta científico-clínica
Angiosarcoma irresecable tratado con bevacizumab y paclitaxel
Unresectable Angiosarcoma Treated With Bevacizumab and Paclitaxel
Leído
9811
Vecesse ha leído el artículo
3162
Total PDF
6649
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 142 | 159 | 301 |
| 2025 5 | 165 | 39 | 204 |
| 2025 4 | 167 | 36 | 203 |
| 2025 3 | 179 | 18 | 197 |
| 2025 2 | 177 | 39 | 216 |
| 2025 1 | 140 | 26 | 166 |
| 2024 12 | 122 | 33 | 155 |
| 2024 11 | 95 | 62 | 157 |
| 2024 10 | 116 | 43 | 159 |
| 2024 9 | 81 | 19 | 100 |
| 2024 8 | 146 | 56 | 202 |
| 2024 7 | 131 | 34 | 165 |
| 2024 6 | 104 | 31 | 135 |
| 2024 5 | 122 | 30 | 152 |
| 2024 4 | 108 | 15 | 123 |
| 2024 3 | 124 | 42 | 166 |
| 2024 2 | 67 | 24 | 91 |
| 2024 1 | 69 | 29 | 98 |
| 2023 12 | 75 | 27 | 102 |
| 2023 11 | 78 | 36 | 114 |
| 2023 10 | 77 | 34 | 111 |
| 2023 9 | 73 | 25 | 98 |
| 2023 8 | 98 | 14 | 112 |
| 2023 7 | 63 | 35 | 98 |
| 2023 6 | 87 | 21 | 108 |
| 2023 5 | 87 | 28 | 115 |
| 2023 4 | 77 | 21 | 98 |
| 2023 3 | 73 | 25 | 98 |
| 2023 2 | 82 | 33 | 115 |
| 2022 1 | 54 | 33 | 87 |
| 2022 12 | 85 | 52 | 137 |
| 2022 11 | 109 | 45 | 154 |
| 2022 10 | 99 | 55 | 154 |
| 2022 9 | 118 | 75 | 193 |
| 2022 8 | 114 | 53 | 167 |
| 2022 7 | 103 | 83 | 186 |
| 2022 6 | 123 | 58 | 181 |
| 2022 5 | 147 | 41 | 188 |
| 2022 4 | 104 | 56 | 160 |
| 2022 3 | 86 | 61 | 147 |
| 2022 2 | 52 | 45 | 97 |
| 2021 1 | 77 | 76 | 153 |
| 2021 12 | 48 | 59 | 107 |
| 2021 11 | 58 | 70 | 128 |
| 2021 10 | 52 | 72 | 124 |
| 2021 9 | 39 | 48 | 87 |
| 2021 8 | 78 | 52 | 130 |
| 2021 7 | 49 | 47 | 96 |
| 2021 6 | 61 | 64 | 125 |
| 2021 5 | 40 | 41 | 81 |
| 2021 4 | 117 | 95 | 212 |
| 2021 3 | 78 | 41 | 119 |
| 2021 2 | 62 | 38 | 100 |
| 2020 1 | 56 | 32 | 88 |
| 2020 12 | 50 | 24 | 74 |
| 2020 11 | 30 | 25 | 55 |
| 2020 10 | 47 | 25 | 72 |
| 2020 9 | 19 | 20 | 39 |
| 2020 8 | 30 | 17 | 47 |
| 2020 7 | 23 | 20 | 43 |
| 2020 6 | 31 | 23 | 54 |
| 2020 5 | 35 | 22 | 57 |
| 2020 4 | 39 | 12 | 51 |
| 2020 3 | 30 | 11 | 41 |
| 2020 2 | 4 | 2 | 6 |
| 2020 1 | 0 | 4 | 4 |
| 2019 12 | 4 | 9 | 13 |
| 2019 11 | 0 | 3 | 3 |
| 2019 10 | 0 | 9 | 9 |
| 2019 9 | 4 | 7 | 11 |
| 2019 8 | 0 | 5 | 5 |
| 2019 7 | 0 | 11 | 11 |
| 2019 6 | 0 | 16 | 16 |
| 2019 5 | 3 | 32 | 35 |
| 2019 4 | 0 | 2 | 2 |
| 2019 3 | 4 | 13 | 17 |
| 2019 2 | 3 | 0 | 3 |
| 2019 1 | 2 | 1 | 3 |
| 2018 12 | 2 | 2 | 4 |
| 2018 11 | 3 | 5 | 8 |
| 2018 10 | 4 | 1 | 5 |
| 2018 9 | 2 | 6 | 8 |
| 2018 8 | 0 | 4 | 4 |
| 2018 7 | 1 | 6 | 7 |
| 2018 6 | 0 | 4 | 4 |
| 2018 5 | 1 | 9 | 10 |
| 2018 4 | 0 | 2 | 2 |
| 2018 3 | 3 | 2 | 5 |
| 2018 2 | 29 | 3 | 32 |
| 2018 1 | 29 | 12 | 41 |
| 2017 12 | 37 | 7 | 44 |
| 2017 11 | 25 | 10 | 35 |
| 2017 10 | 30 | 12 | 42 |
| 2017 9 | 39 | 8 | 47 |
| 2017 8 | 33 | 15 | 48 |
| 2017 7 | 26 | 8 | 34 |
| 2017 6 | 36 | 13 | 49 |
| 2017 5 | 23 | 13 | 36 |
| 2017 4 | 34 | 14 | 48 |
| 2017 3 | 24 | 35 | 59 |
| 2017 2 | 40 | 10 | 50 |
| 2016 1 | 34 | 12 | 46 |
| 2016 12 | 30 | 9 | 39 |
| 2016 11 | 38 | 15 | 53 |
| 2016 10 | 48 | 18 | 66 |
| 2016 9 | 44 | 13 | 57 |
| 2016 8 | 36 | 12 | 48 |
| 2016 7 | 35 | 7 | 42 |
| 2016 6 | 10 | 10 | 20 |
| 2016 5 | 6 | 4 | 10 |
| 2016 4 | 3 | 3 | 6 |
| 2016 3 | 5 | 0 | 5 |
| 2016 2 | 10 | 2 | 12 |
| 2015 1 | 14 | 1 | 15 |
| 2015 12 | 9 | 1 | 10 |
| 2015 11 | 4 | 0 | 4 |
| 2015 10 | 8 | 1 | 9 |
| 2015 9 | 5 | 0 | 5 |
| 2015 8 | 9 | 2 | 11 |
| 2015 7 | 42 | 3 | 45 |
| 2015 6 | 40 | 3 | 43 |
| 2015 5 | 47 | 5 | 52 |
| 2015 4 | 35 | 8 | 43 |
| 2015 3 | 23 | 4 | 27 |
| 2015 2 | 18 | 13 | 31 |
| 2015 1 | 18 | 12 | 30 |
| 2014 12 | 23 | 11 | 34 |
| 2014 11 | 15 | 6 | 21 |
| 2014 10 | 32 | 7 | 39 |
| 2014 9 | 12 | 3 | 15 |
| 2014 8 | 19 | 4 | 23 |
| 2014 7 | 27 | 8 | 35 |
| 2014 6 | 32 | 20 | 52 |
| 2014 5 | 5 | 5 | 10 |
Mostrar todo
